Imaging-derived biomarkers in Asthma: Current status and future perspectives

Asthma is a common disorder affecting around 315 million individuals worldwide. The heterogeneity of asthma is becoming increasingly important in the era of personalized treatment and response assessment. Several radiological imaging modalities are available in asthma including chest x-ray, computed tomography (CT) and magnetic resonance imaging (MRI) scanning. In addition to qualitative imaging, quantitative imaging could play an important role in asthma imaging to identify phenotypes with distinct disease course and response to therapy, including biologics. MRI in asthma is mainly performed in research settings given cost, technical challenges, and there is a need for standardization. Imaging analysis applications of artificial intelligence (AI) to subclassify asthma using image analysis have demonstrated initial feasibility, though additional work is necessary to inform the role of AI in clinical practice. •In clinical practice, imaging among patients with asthma is mainly performed in the acute setting.•Novel non-invasive disease biomarkers can be utilized across the full spectrum of the disease.•Quantitative imaging could play an important role in personalized treatment and response assessment in asthma.